AbbVie Inc (ABBV) : Creative Planning scooped up 20,173 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 256,303 shares of AbbVie Inc which is valued at $15,990,744.AbbVie Inc makes up approximately 0.10% of Creative Planning’s portfolio.
Other Hedge Funds, Including , Canandaigua National Bank Trust Co reduced its stake in ABBV by selling 817 shares or 2.36% in the most recent quarter. The Hedge Fund company now holds 33,775 shares of ABBV which is valued at $2,107,222. AbbVie Inc makes up approx 0.62% of Canandaigua National Bank Trust Co’s portfolio.Hudson Valley Investment Advisors Inc Adv reduced its stake in ABBV by selling 150 shares or 0.83% in the most recent quarter. The Hedge Fund company now holds 17,922 shares of ABBV which is valued at $1,134,642. AbbVie Inc makes up approx 0.35% of Hudson Valley Investment Advisors Inc Adv’s portfolio.Advisory Services Network boosted its stake in ABBV in the latest quarter, The investment management firm added 5,555 additional shares and now holds a total of 9,290 shares of AbbVie Inc which is valued at $584,620. AbbVie Inc makes up approx 0.11% of Advisory Services Network’s portfolio.Catawba Capital Management Va boosted its stake in ABBV in the latest quarter, The investment management firm added 535 additional shares and now holds a total of 40,577 shares of AbbVie Inc which is valued at $2,553,511. AbbVie Inc makes up approx 0.61% of Catawba Capital Management Va’s portfolio.
AbbVie Inc closed down -0.92 points or -1.45% at $62.39 with 53,08,425 shares getting traded on Tuesday. Post opening the session at $63.08, the shares hit an intraday low of $62.05 and an intraday high of $63.26 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by JP Morgan to ” Neutral” on Sep 8, 2016. Raymond James Initiated AbbVie Inc on Sep 2, 2016 to “Outperform”, Price Target of the shares are set at $82.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.